MENLO PARK, Calif., July 7, 2021 – SRI International (SRI) today announced that the company has entered a research collaboration with Sanofi. By leveraging SRI’s SynFini™ platform, an artificial intelligence (AI)-guided, automated synthetic-chemistry system, the collaboration will discover and develop lead candidates in multiple high-profile drug-discovery programs at Sanofi.
SRI’s SynFini platform combines AI and automation to accelerate small molecule drug discovery and development, and thereby bring new drugs to the clinic more quickly and affordably. The platform comprises three components (SynRoute™, SynJet™ and AutoSyn™) that work seamlessly together to automate synthetic route design, reaction screening and optimization (RSO), and production of target molecules.
“The goal of the SynFini platform is to create a new paradigm in the approach to drug discovery,” said Nathan Collins, chief strategy officer of SRI’s Biosciences Division and head of the SynFini program. “We look forward to working with Sanofi in applying our AI-guided automation platform to drive the rapid and efficient discovery of therapeutics for high-profile targets.”
The SRI-Sanofi collaboration will also use SRI’s recently implemented DASLTM (Deep Adaptive Semantic Logic) AI-guided molecular design tool for multi-parametric optimization in hit-to-lead and lead optimization. Utilizing reasoning-guided deep neural networks, DASL efficiently predicts drug designs from the sparse data sets that are typically available in drug discovery.
About SRI International
SRI International creates world-changing solutions making people safer, healthier and more productive. SRI, a research center headquartered in Menlo Park, California, works primarily in advanced technology and systems, biosciences, computing and education. SRI brings its innovations to the marketplace through technology licensing, spin-off ventures and new product solutions.
# # #
For SRI International